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Abstract: Background Adding a long-acting β2-agonist (LABA) to inhaled 
corticosteroids (ICS) using a fixed-dose combination (FDC) inhaler 
containing ICS and LABA is the UK guideline-recommended step-up option 
for children aged >4 years with uncontrolled asthma on ICS monotherapy. 
The evidence of benefit of FDC inhalers over adding a separate LABA 
inhaler to ICS therapy is limited.  
Objective: Our aim was to compare outcomes for FDC versus separate 
LABA+ICS inhalers for children by analyzing routinely-acquired clinical 
and prescribing data. 
Methods This matched cohort study used large UK primary care databases to 
study children prescribed their first step-up from ICS monotherapy at 5-
12 years of age as add-on LABA, either via separate LABA inhaler or FDC 
inhaler. A baseline year was examined to characterize patients and 
identify potential confounders; outcomes were examined during the 
subsequent year. The primary outcome was adjusted odds ratio for overall 
asthma control, defined as no asthma-related hospital admission, 
emergency room visit prescription for oral corticosteroids and ≤200 
μg/day salbutamol. 
Results After matching, there were 1330 children in each cohort (mean age 
[SD] 9 [2] years; 59% male). All measures of asthma exacerbations and 
control improved during the outcome year in both cohorts. In the separate 
ICS+LABA cohort, the odds of achieving overall asthma control were lower 
(adjusted odds ratio, 0.77 [95% CI 0.66-0.91] P = 0.001) compared with 
the FDC cohort.   
Conclusion Our results demonstrate a small but significant benefit of 
add-on LABA therapy as FDC over separate inhaler and support current 
recommendations. 
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reviewers and the editorial team for their very helpful suggestions.  We have made considerable changes 
to the previous version submitted in response to the comments raised after our most recent submission.  
Our point by point response follows this message. 
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EDITOR'S SPECIFIC COMMENTS: 
We appreciate your patience with our review process, but there are several additional issues that need to 
be addressed which before it is completed. The revision will improve the readability of the manuscript for 
our readers. 
 
1. The manuscript needs to be written in better scientific style with more easily to read sentences. In 
addition, please assure that American English spelling is used throughout the manuscript, i.e., 
hospitalization instead of hospitalisation. Please check the paper carefully as there are many punctuation 
errors. Also many sentences are too long and can easily be shortened or divided into two sentences to 
improve readability. Just 2 of many examples: Lines 300-305, 322-326. Step up should be hyphenated: 
step-up. 
 
Complete edit of writing style has been carried out. 
 
2. Please be consistent in terminology: suggest whenever ICS+LABA is noted it should be more precise 
and writing as separate ICS+LABA.  See line 246 which notes, "ICS+LABA as separates cohort." 
 
Terminology amended to be consistent 
 
 
3. Tables and Figures should be capitalized throughout the text. Numbering should be in increasing 
roman numbers, e.g., Table I, Table II. For the online repository tables should written as Table E1, Table 
E2, etc. 
 
Done 
 
4. Lines 61-62: This definition of asthma control used for the study appears incomplete: Table 1 notes "All 
of the following: no asthma-related hospital admission; no emergency room or outpatient attendance for 
asthma; no prescription for OCS or antibiotic with evidence of respiratory consultation; average daily 
prescribed dose of ≤200 <mu>g/day salbutamol or ≤500 <mu>g/day terbutaline (equivalent to ≤2 puffs 
daily of reliever medication)." I suggest the following change: defined as no asthma-related hospital 
admission, emergency room visit, prescription for oral corticosteroids or antibiotic with evidence of 
respiratory consultation, and ≤2 puffs of short-acting beta-agonist daily. 
 
Suggested change made (lines 71-73 in revised document with tracked changes) 
 
5. Lines 64-65: Please remove exacerbations since the abstract should emphasize the primary outcome: 
control. I suggest changing the sentence to "Asthma control improved during the outcome year in both 
cohorts." 
 
Suggested change made (lines 77-78) 
Responses to Comments
 
6. Lines 70-71: Suggest modifying to: The study demonstrates a small but significant benefit in achieving 
asthma control form add-on LABA therapy as FDC with ICS compared to a separate inhaler with ICS which 
supports current guideline recommendations. 
 
Suggested change made (lines 81-83) 
 
 
7. Line 127: The readers are not familiar with your study databases and other terms and it is suggested 
that they not be abbreviated throughout. Moreover several are cited infrequently in the text. Please also 
remove them from the abbreviation section. CPRD, OPCRD, ADEPT. 
 
Changed to full wording and removed from list of abbreviations 
 
 
8. Line 131: Reference in parenthesis needs to be added to citations: ref ENCEPP/SDPP/10483 
 
Number written is registration number for study.  So this has been kept in, but a new 
reference has now also been added for the website of ENCEPP (line 146, ref 19) 
 
9. Lines 155-159: Please add back the primary outcome definition since it should be in the text. It can also 
be in Table I. 
 
Done (lines 180-183) 
 
10. Line 224: Please define what is meant by OOPCRD and do not abbreviate. 
 
Done (line 256) 
 
11. Lines 226 and elsewhere: data should be written with the words 95% CI, as : 0.77 (95% CI, 0.66-0.91; P 
= 0.001). 
 
Changed to be consistent with the rest 
 
12. Line 237: achieving not achieve 
 
Changed (line 270) 
 
13. Lines 270-271: Please provide the % of patients in addition to the number that switched drug 
categories. 
 
Done (lines 307-310) 
 
14. Line 287: inhalers should be plural. 
 
Changed (line 317) 
 
15. Line 297: Do you mean 1 additional child gain control? 
 
Yes – wording changed to avoid ambiguity (line 335) 
 
16. Lines 300-305: Sentence too long, please improve its presentation. 
 
Addressed in general edit of writing style 
 
17. Line 309: Please add short duration rather than just short. 
 
Changed (lines 352) 
 
18. Lines 318-324: Purely speculative and should be deleted. 
 
Done (lines 361-368) 
 
 
19. Line 346: Is there a better word than 'covert'? 
 
Word now omitted (line 393) 
 
20. Line 360: The 'SMART' regimen has not been described previously in the manuscript and needs to be 
noted if it is to be discussed. 
 
Brief description and new reference (Chapman 2010) has been added. (lines 403-404, ref 
40) 
 
21. Lines 411-413: Please delete as not an important new finding from this study. 
 
Line has been re-phrased to have it read as a method rather than a finding (lines 454-456)  
 
22. Line 414: Why is the term whole population needed in this sentence? 
 
Removed(line 457) 
 
23. Table 1: Title seems inaccurate as it includes the primary outcome for this manuscript. Perhaps more 
accurate would be "Definitions of database-derived primary and secondary study outcomes." 
 
Suggested change made 
 
 
24. The following should be added footnote to the table: "Definitions of oral corticosteroid use and 
respiratory consultation are provided in the supplement." 
 
Added as footnote 
 
 
COMMENTS FROM REVIEWER #1: 
The authors have responded well to the previous comments.  The revised manuscript is improved and 
reads well. 
 
 
COMMENTS FROM REVIEWER #2: 
I have again re-reviewed your paper entitled 'Long-acting beta-agonist in combination or separate inhaler 
as step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids' and still have 
some questions/concerns: 
 
1. Line 607: Please comment on the following: since extra-fine ICS has much greater lung deposition than 
standard ICS an equivalent dose would be 1/2, not double. 
 
Changed to “halved” (footnote, table II) 
 
2. As with my previous reviews I find disturbing that the various outcome measures not to improve 
much  by either preparation in the post year presumably because adherence as measured by MPR, which 
has been reported not to be as rigorous as the AMR by Schatz in this journal recently, was extremely 
poor. This certainly does not explain the difference in the 2 cohorts. One would think 1 device would 
result in better adherence than 2. Need to explain this finding. I suspect these cohorts would have done 
well on Step 2 with improved adherence. To me these results are consistent with primary care 
management in general where patient education is poor, guidelines are not followed, and most 
important continuity of care by the same physician is sorely lacking. I would think this would merit some 
thought and comment. 
 
New sentence (with reference) has been added to clarify point: “An additional factor may 
be that adherence was relatively poor for all participants (22-33%) and poor adherence is 
associated with poor control.
30
 This may have led to the decision to step-up and also to a 
relatively disappointing response to treatment.  National guidelines
3
 recommend that 
before initiating a new drug therapy, adherence to existing therapies should be 
considered, as well as inhaler technique and the elimination of trigger factors. The 
adherence in our study suggests that this may not be happening routinely.”  -- (lines 337-
343, ref 30) 
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What is already known about this topic? 32 
Current asthma guidelines recommend that children prescribed long-acting β2-agonist 33 
(LABA) should receive treatment as a fixed-dose combination inhaler, rather than as an 34 
additional, separate inhaler alongside inhaled corticosteroids (ICS). Current literature, 35 
however, does not provide evidence to support this.  36 
What does this article add to our knowledge?  37 
In a matched cohort study, LABA treatment as a separate inhaler was associated with 38 
poorer asthma control compared to a fixed-dose combination inhaler. 39 
How does this study impact current management guidelines? 40 
These findings support recommendations from British Thoracic Society, NICE asthma 41 
guideline and Food and US Drug Administration, to prescribe add-on LABA as a fixed-dose 42 
combination inhaler with ICS in children. 43 
  44 
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ABSTRACT  45 
Background Adding a long-acting β2-agonist (LABA) to inhaled corticosteroids (ICS) using a 46 
fixed-dose combination (FDC) inhaler is the UK guideline recommendation for children aged 47 
>4 years with uncontrolled asthma. The evidence of benefit of adding a FDC inhaler over a 48 
separate LABA inhaler is limited.  49 
Objective Our aim was to compare effectiveness of LABA added as a FDC inhaler, and as a 50 
separate inhaler, in children with uncontrolled asthma.  51 
Methods Two UK primary care databases were used to create a matched cohort study with 52 
a two-year follow-up period.  We included children prescribed their first step-up from ICS 53 
monotherapy. Two cohorts were formed for children receiving add-on LABA as FDC inhaler, 54 
or separate LABA inhaler. Matching variables and confounders were identified by comparing 55 
characteristics during a baseline year of follow-up. Outcomes were examined during the 56 
subsequent year. The primary outcome was an adjusted odds ratio for overall asthma 57 
control (defined as; no asthma-related hospital admission or emergency room visit, 58 
prescription for oral corticosteroids or antibiotic with evidence of respiratory consultation, and 59 
≤2 puffs of short-acting beta-agonist daily). 60 
Results The final study consisted of 1330 children in each cohort (mean age 9 years [SD, 61 
2]; 59% male). In the separate ICS+LABA cohort, the odds of achieving overall asthma 62 
control were lower (adjusted odds ratio, 0.77 [95% CI, 0.66-0.91] P = 0.001) compared with 63 
the FDC cohort.   64 
Conclusion The study demonstrates a small but significant benefit in achieving asthma 65 
control from add-on LABA as FDC, compared to a separate inhaler which supports current 66 
guideline recommendations. 67 
 68 
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INTRODUCTION 70 
Asthma is common amongst children in the UK, with an estimated 8%, or 1.1 million 71 
children, prescribed current asthma therapy.1,2 The British Thoracic Society and Scottish 72 
Intercollegiate Guidelines Network (BTS/SIGN) guideline for the management of asthma 73 
recommends a stepwise approach to therapy, to maintain symptom control and minimize 74 
future risk of exacerbations. Inhaled corticosteroids (ICS), prescribed at step 2 of the current 75 
BTS/SIGN guideline, are effective controller medications for most children with persistent 76 
asthma.  For 10–25% of children with asthma, additional therapy is required.3-6 For children 77 
aged 5-12 years on ICS monotherapy, adding a long-acting β2-agonist (LABA) is the 78 
preferred step-up option (step 3) recommended by the BTS/SIGN when asthma is 79 
uncontrolled.3 80 
 Guidance from the UK National Institute for Health and Care Excellence (NICE) 81 
identifies a fixed-dose combination (FDC) inhaler containing ICS and LABA as the optimal 82 
means of adding a LABA.2 However, some children continue to be prescribed separate 83 
inhalers. One risk of prescribing LABA as a separate inhaler is its use without concomitant 84 
ICS therapy. This is a major concern discussed in the National Review of Asthma Deaths.7 85 
The benefit of FDC over addition of a separate LABA inhaler to ICS treatment for 86 
children with uncontrolled asthma is unclear. Two clinical trials, where adherence was 87 
closely monitored, found no difference in symptoms after 3 months 8 and 6 months9, when 88 
comparing groups randomized to LABA as separate inhaler or FDC. However, patient 89 
behavior and clinical outcomes are often different in the context of a clinical trial as opposed 90 
to ‘real-life’ usual clinical care. One database study using real-life data observed a reduced 91 
need for short-acting β2-agonist (SABA) and oral corticosteroid (OCS) treatment in children 92 
treated with LABA as an FDC compared with a separate inhaler.4  These results are limited, 93 
however, as there was no matching at baseline for factors known to be different between 94 
groups, including age and obesity.10 We have recently reported that children stepped up to 95 
LABA as a separate inhaler are younger and on a lower dose of ICS compared with those 96 
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stepped up to FDC.10 These baseline differences might explain the apparent superiority of 97 
FDC over LABA as separate inhaler.   98 
Rigorously conducted observational research can provide information about 99 
outcomes of asthma therapy under conditions of usual clinical practice, to complement 100 
information from controlled trials.11 Results of prior retrospective observational studies 101 
suggest that adherence and refill persistence may be better with a combination inhaler, at 102 
least among adults and adolescents.12-14 In turn, better adherence and persistence could 103 
lead to better outcomes. The aim of this large population-based observational study was to 104 
compare outcomes between children stepped up to add-on LABA as separate inhalers, 105 
versus those receiving FDC inhalers. Our hypothesis was that children stepped up to 106 
separate inhalers would have reduced odds for achieving asthma control compared with 107 
matched children stepped up to FDC. 108 
  109 
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METHODS 110 
Data source and permissions 111 
In a matched cohort study, we sourced medical records and prescribing data from two large 112 
primary care databases including ~15% of children in the UK, as previously described.10 113 
Duplicate records from individual children were identified and removed. The Clinical Practice 114 
Research Datalink (CPRD; formerly General Practice Research Database) is well-validated 115 
and used frequently for observational research.  It is the world’s largest repository of 116 
anonymized longitudinal data from primary care, drawing from over 600 subscribing 117 
practices throughout the UK.15,16 The Optimum Patient Care Research Database (OPCRD) 118 
is a quality-controlled primary care research database, containing information from over 400 119 
UK practices caring for approximately half a million patients with asthma.17 As well as 120 
anonymous medical records, the database contains patient-completed questionnaire data. 121 
Data were available from January 1990 through April 2012 for the Clinical Practice Research 122 
Datalink and through December 2012 for the Optimum Patient Care Research Database. 123 
 The study was conducted to standards recommended for observational research18 124 
and is registered with the European Network of Centres for Pharmacoepidemiology and 125 
Pharmacovigilance.19 (ref ENCEPP/SDPP/10483). Use of the data was approved in 2010 by 126 
the Independent Scientific Advisory Committee of the (then) General Practice Research 127 
Database. The Optimum Patient Care Research Database has been approved by the Trent 128 
Multi Centre Research Ethics Committee for clinical research use. The protocol for this study 129 
was approved by the Anonymized Data Ethics Protocols and Transparency (ADEPT) 130 
committee - the independent scientific advisory committee for the Optimum Patient Care 131 
Research Database. Further background information is available in the online 132 
supplementary material. 133 
Inclusion and exclusion criteria 134 
Our study included a two-year period of follow-up, consisting of a baseline year and an 135 
outcome year, on either side of an index date. The index date was the point at which step-up 136 
LABA therapy was initiated.  General patient information and events during the baseline year 137 
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were used to determine which individuals entered the study sample. Inclusion criteria were: 138 
either a read code diagnosis of asthma or 2 or more inhaler prescriptions (at least 1 of which 139 
was for ICS in the previous 12 months) - the latter comprise 2% of the study population10; 140 
prescription of step-up with LABA, from ICS monotherapy at 5–12 years of age; registered in 141 
the database for at least 2 sequential years, including 1 baseline year before the date of 142 
therapy step-up (index date). Exclusion criteria were: cystic fibrosis or any chronic 143 
respiratory disease other than asthma; receipt of add-on therapy (including combination 144 
inhaler) at any time prior to the index date; treatment with oral corticosteroids (OCS) for 145 
more than 7 consecutive days during the baseline year; multiple step-up therapies on the 146 
index date; ≥50% increase or decrease in ICS dose on the index date (the latter ensured 147 
that we studied outcomes of addition of LABA independent of change in ICS).  148 
Study Outcomes 149 
The primary endpoint, previously described20-22, was an adjusted odds ratio (aOR) for overall 150 
asthma control. This compared two study cohorts: those who received step-up LABA as an 151 
FDC inhaler (FDC ICS/LABA cohort), and those who received a separate LABA inhaler 152 
(separate ICS+LABA cohort). The definition of asthma control includes both components of 153 
the American Thoracic Society/European Respiratory Society23 definition, i.e. the level of 154 
clinical asthma control (as evidenced here by short acting beta agonist use) and the risk of 155 
future adverse events (as evidenced here by a history of adverse events including 156 
hospitalisation, emergency visits and receipt of OCS).  The criteria for overall asthma 157 
control, as defined in Table I, include: no asthma-related hospital admission; no emergency 158 
room or outpatient attendance for asthma; no prescription for OCS or antibiotic with 159 
evidence of respiratory consultation; average daily prescribed dose of ≤200 µg/day 160 
salbutamol or ≤500 µg/day terbutaline (equivalent to ≤2 puffs daily of reliever medication). 161 
Hospital admission, emergency room attendance and unscheduled outpatient attendance 162 
were coded from discharge diagnosis.  A prescription for antibiotics in conjunction with a 163 
respiratory consultation was included in the definition of an acute respiratory event (and 164 
absence of same in the definitions of asthma control) because in clinical practice antibiotics 165 
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may be prescribed for an asthma exacerbation.24-26 Secondary outcomes were acute 166 
respiratory events, severe exacerbations,23 risk-domain measure of asthma control (to give 167 
insight into risk for future exacerbation)20-22  and treatment stability (see Table I for 168 
definitions).  Medication use during the 12 months after the index date was also compared 169 
between cohorts.   170 
Calculations of medication use 171 
We calculated the average daily doses of SABA and of ICS during the baseline and outcome 172 
years in the following way: 173 
                                      
   
                          
 For ICS doses we used the beclomethasone dipropionate (BDP)-equivalent doses for the 174 
calculations, thus: a 1:1 ratio for budesonide:BDP; a 2:1 ratio for fluticasone propionate:BDP, 175 
and; a 2:1 ratio for extrafine beclomethasone (Qvar):BDP. The ICS medication possession 176 
ratio (MPR) was calculated as: 177 
                                          
   
        
Individuals were categorized as either non-adherent (MPR<80%), or adherent 178 
(MPR≥80%).27,28 The separate LABA inhalers that were available during the study period 179 
contained salmeterol or formoterol The FDC ICS/LABA inhalers contained fluticasone-180 
salmeterol (Seretide), budesonide-formoterol (Symbicort), and extrafine beclomethasone-181 
formoterol (Fostair). 182 
Statistical analyses and sample size 183 
Children in the two treatment cohorts were matched sequentially 1:1 on the following criteria, 184 
which were known to differ at baseline4: year of index date (±3 years), age (exact year), 185 
number of severe exacerbations (0 or ≥1) during baseline year, prior ICS daily dose (≤150, 186 
151–250, 251–500, or >500 µg/day), and mean daily SABA dose (0, 1–200, >200 µg/day) 187 
during baseline year. Bespoke software was used to randomly select unique matched 188 
patient pairs when more than one match was possible. 189 
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 Data were prepared for analysis by investigating potential outliers, transforming 190 
skewed data (e.g., log transformation), and categorizing heavily skewed data. Missing data 191 
were investigated for type and reason for missingness. Summary statistics were computed, 192 
by cohort, for baseline characteristics and outcome events. They were compared using 193 
conditional logistic regression (unadjusted). 194 
Conditional logistic regression models were used to estimate adjusted odds ratios 195 
(aOR) and 95% confidence intervals (CIs) for the dichotomous outcomes, such as the 196 
primary endpoint - overall asthma control.  The reference cohort was the FDC ICS/LABA 197 
cohort. 198 
The rates of adverse respiratory events and severe exacerbations during the 199 
outcome year were compared using a negative binomial regression model. Adjusted rate 200 
ratios (aRR) were computed with 95% CIs, with FDC ICS/LABA cohort as the reference 201 
cohort. General estimating equations were used to account for the correlation within 202 
matched pairs.29 The model used empirical standard errors for more robust confidence 203 
intervals. 204 
 For all multivariable models, those variables that were significantly different or 205 
showed a trend towards a difference (P < 0.10) between the treatment cohorts at baseline 206 
were included as potential confounding factors, along with any strongly predictive variables. 207 
Potential confounders examined are listed in the online supplementary material (Table E1). 208 
Variables were examined for collinearity and clinical importance and were then removed in a 209 
backwards stepwise procedure until all confounding variables remaining in the multivariable 210 
model had P < 0.1 (see online supplementary material for further details).  211 
All analyses were done on an intention-to-treat basis, i.e. children remained in their original 212 
cohort even if their treatment method changed during the outcome year. Statistical 213 
significance was set at the 5% level, i.e. P < 0.05. No prospective power calculation was 214 
carried out since our sample size was determined by the number of eligible children in the 215 
Clinical Practice Research Datalink and Optimum Patient Care Research Database.  216 
  Turner et al.  11 
 
 11 
The analyses were carried out using IBM SPSS Statistics version 21 (SPSS 217 
Statistics, IBM, Somers, NY, USA), SAS version 9.3 (SAS Institute, Marlow, 218 
Buckinghamshire, UK), and Microsoft Excel 2007 (Microsoft, Bellevue, WA, USA).  219 
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RESULTS 220 
Patients 221 
Overall, 1390 and 3771 children were eligible for the FDC ICS/LABA and separate 222 
ICS+LABA cohorts, respectively (see Figure E1 in supplementary file). Ninety seven percent 223 
of children had a diagnosis of asthma and 70% were from the Optimum Patient Care 224 
Research Database.  After matching there were 1330 children in each cohort, of mean age 9 225 
years (SD, 2), and 59% were male (Table II). The two cohorts were similar in characteristics 226 
apart from the separate ICS+LABA cohort having: higher dose of ICS at baseline; higher 227 
annualized ICS dose, and; LABA step-up occurring one year earlier (i.e. 2005 versus 2006) 228 
compared to the FDC cohort (Table II and Table E2).The cohorts were well-matched for 229 
indicators of baseline asthma severity and control (Table III).  230 
 231 
Outcomes 232 
Primary outcome 233 
In the FDC ICS/LABA cohort, the proportion of children who achieved overall asthma control 234 
was 35% before the index date and 43% afterwards. Equivalent proportions in the separate 235 
ICS+LABA cohort were 35% and 37% (Table III). The adjusted odds ratio (aOR) for children 236 
in the separate ICS+LABA cohort achieving control relative to the FDC ICS/LABA cohort 237 
was 0.77 (95% CI, 0.66–0.91; P = 0.001; Figure I).   238 
Secondary outcomes 239 
The number of acute respiratory events was greater among the separate ICS+LABA cohort 240 
compared to the FDC ICS/LABA cohort (Table III). The adjusted rate ratio (aRR) was 1.21 241 
(95% CI, 1.04–1.39; P = 0.012; Figure I).  The percentage of children with ≥1 severe 242 
exacerbations was 13% during the baseline year for both cohorts and in the outcome year 243 
was 7% for the FDC ICS/LABA cohort and 9% for the separate ICS+LABA cohort. The aRR 244 
for severe exacerbations was 1.31 (95% CI, 0.99–1.72; P = 0.056). Relative to the FDC 245 
ICS/LABA cohort, children in the separate ICS+LABA cohort had reduced odds for achieving 246 
risk-domain asthma control (aOR 0.74; 95% CI, 0.61–0.89; P = 0.003) and achieving 247 
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treatment stability (aOR 0.67; 95% CI, 0.57–0.79; P < 0.001; Figure I). There were no 248 
significant differences between cohorts for adherence (MPR>80%) or for severe 249 
exacerbations.  In the outcome year there were 6 hospitalizations for asthma in each cohort.  250 
There were 16 children in the FDC ICS/LABA cohort and 3 in the separate ICS+LABA cohort 251 
treated for thrush (P = 0.008, Table E2).  Compared to the baseline year, more children in 252 
the separate ICS+LABA cohort (29.9% in baseline year and 22.5% in follow up year) 253 
received treatment with antibiotics during the follow-up year than in the FDC cohort (28.6% 254 
and 19.6% respectively, P = 0.041).  There was a trend which approached significance for a 255 
greater proportion of the separate ICS+LABA cohort to receive OCS compared to the FDC 256 
ICS/LABA cohort during the outcome year (8.8% versus 6.5%, p=0.084).  257 
Asthma prescribing during outcome year 258 
Asthma therapy prescribed during the outcome year, as well as changes in therapy, are 259 
summarized in Table IV. Children in the FDC ICS/LABA cohort typically received one fewer 260 
SABA inhalers in the outcome year compared with those in the separate ICS+LABA cohort 261 
(3 vs. 4 inhalers; P < 0.001). Children in the FDC ICS/LABA cohort were more likely to have 262 
an increase in ICS dose compared with those in the separate ICS+LABA cohort (10% vs. 263 
4%; P < 0.001), but no more likely to have LTRA added. The proportion of children achieving 264 
adherence (MPR>80%) was 33% in the FDC ICS/LABA cohort and 31% in the separate 265 
ICS+LABA cohort (aOR 0.87; 95% CI, 0.72–1.06). During the outcome year the median daily 266 
ICS dose was 219 μg for both cohorts. Further, during the outcome year 231 (18%) children 267 
in the separate ICS+LABA cohort switched to FDC, and 17 (1%) children in the FDC 268 
ICS/LABA cohort switched to a separate LABA inhaler. LTRA treatment was started in 122 in 269 
the FDC ICS/LABA cohort (9%) and 112 in the separate ICS+LABA cohort (8%).  270 
 271 
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DISCUSSION 272 
The aim of this matched cohort study was to provide evidence to support guideline 273 
recommendations that children receiving LABA as an add-on to ICS treatment should be 274 
prescribed a fixed-dose combination inhaler (FDC) and not an additional, separate LABA 275 
inhaler. It is an important point to establish as prescription of separate inhalers remains very 276 
common in UK clinical practice, despite recommendations.2,3 The main finding was that 277 
children prescribed add-on LABA with ICS as separate inhalers had a 23% reduced odds of 278 
having controlled asthma compared with children prescribed FDC.  Additionally the use of 279 
separate inhalers was associated with a 21% greater rate of acute respiratory events 280 
compared with those who received FDC. The fact that 17% of children in the separate 281 
ICS+LABA cohort were prescribed an FDC inhaler during the outcome year suggests that 282 
prescribers may be trialing LABA as a separate inhaler. Our data suggest that the trial 283 
should be with FDC in the first instance. Our results provide additional evidence that 284 
supports guideline recommendations for LABA to be prescribed as FDC, and not as a 285 
separate, inhaler.2,3    286 
Although significant, the improvement in outcomes for those treated with FDC was 287 
only by a small degree compared with treatment with separate ICS and LABA inhalers.   We 288 
used an intention-to-treat analysis, but as 17% of the separate ICS+LABA cohort received 289 
FDC during the follow up, this will underestimate the true clinical benefit of FDC over 290 
separate ICS+LABA inhalers.   We present our results as odds ratios, and the effect size is 291 
small when presented as a likelihood ratio for achieving control (0.9 for the separate 292 
ICS+LABA cohort compared to the FDC ICS/LABA cohort), or as the number needed to treat 293 
(17 children would require treatment with FDC instead of a separate inhaler in order for one 294 
additional child to achieve asthma control). This small effect may be partly explained by 295 
improvement in all outcomes in both groups as the children became older. An additional 296 
factor may be that adherence was relatively poor for all participants (22-33%) and poor 297 
adherence is associated with poor control.30 This may have led to the decision to step-up 298 
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and also to a relatively disappointing response to treatment.  National guidelines3 299 
recommend that before initiating a new drug therapy, adherence to existing therapies should 300 
be considered, as well as inhaler technique and the elimination of trigger factors. The 301 
adherence in our study suggests that this may not be happening routinely.   302 
 There is little prior published work comparing outcomes with FDC versus separate 303 
inhalers for children prescribed add-on LABA, yet many thousands of children are prescribed 304 
LABA each year. Outcomes were similar with FDC versus separate inhalers for children in 305 
two double-blind, double-dummy trials with relatively short duration,8,9 although one trial did 306 
observe a greater increase in peak expiratory flow in children receiving FDC compared to 307 
separate inhalers.9 These studies might have been underpowered to detect differences 308 
between two effective treatments, and additionally it is well-recognized that clinical trials 309 
recruit individuals whose disease is exceptionally stable and whose adherence behavior is 310 
not generalizable to the whole population. This potentially reduces the ability of clinical trials 311 
to detect a difference in outcome between treatment groups.18 A recent retrospective 312 
observational database study observed that children prescribed FDC inhalers received fewer 313 
acute oral corticosteroid courses and, in 2 of the 4 years studied, also less reliever 314 
medication than those prescribed separate inhalers.4    315 
 The use of an FDC ICS/LABA inhaler has several theoretical benefits over two 316 
separate inhalers. The concurrent delivery of a bronchodilator (LABA) may provide a 317 
symptomatic benefit with use of FDC inhalers that promotes inhaler use, and thus may lead 318 
to improved adherence with treatment and increased consumption of concomitant ICS.31,32 319 
Other authors have hypothesized there may be a biochemical synergy between ICS and 320 
LABA with their co-deposition in the airways.33,34 Moreover, an important advantage of 321 
combining ICS and LABA in one inhaler is the prevention of LABA use as monotherapy, 322 
which carries potential increased risk of asthma-related mortality. Since 2005 LABA 323 
monotherapy is accompanied by a Food and Drug Administration (FDA) “black box” warning 324 
in the US.35,36 In 2010, the FDA recommended the use of FDC products to ensure 325 
compliance with concomitant therapy in pediatric and adolescent patients.37 Conversely, an 326 
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advantage of prescribing separate inhalers is the ability to titrate ICS dose independently of 327 
the LABA. 328 
 The assumption of better LABA adherence with use of a single FDC ICS/LABA 329 
inhaler rather than two separate inhalers is generally acknowledged.2 We found no evidence 330 
for improved ICS adherence between cohorts, in terms of refill prescription rates. However, 331 
the increased number of children treated for thrush in the FDC ICS/LABA compared to the 332 
separate ICS+LABA cohort might suggest increased adherence with ICS in the FDC cohort, 333 
but may reflect a lower proportion using a spacer device compared to the separate cohort.  334 
Some retrospective observational studies find that FDC inhalers are associated with better 335 
adherence and refill persistence by both adults and adolescents with asthma,12-14 but this 336 
finding is not seen in all studies. For example, in one randomized controlled trial (patients 337 
aged 16–65 years) where electronic monitoring was used to measure adherence, similar 338 
adherence was found with FDC and separate inhaler therapy.38 In a retrospective 339 
observational study, and consistent with our findings, Elkout et al.39 found that MPR was 340 
similar for children prescribed separate ICS and LABA inhalers and FDC only. Further, it is 341 
possible that although separate ICS and LABA inhalers are issued with equal frequency, 342 
adherence with ICS is higher compared with separate LABA inhalers. Clearly more research 343 
is needed in this area but the limited data from children presented here and from adults 344 
elsewhere38 suggest that FDC is associated with superior outcomes. Potentially, this may be 345 
explained by different taking behavior, e.g. taking more separate inhalers when 346 
symptomatic. 347 
 Treatment with a “SMART” regimen40 (which utilizes a combination inhaler with both 348 
preventer and reliever medication) has never been recommended for children in the UK, and 349 
our study cannot give insight into the potential benefits of this practice.  There is evidence of 350 
reduced exacerbations in children randomized to a “SMART” regimen compared with FDC41 351 
but this work has not been confirmed elsewhere or incorporated into guidelines to date.  352 
Antibiotics are not recommended for the treatment of acute asthma excerbations in 353 
any age group, but since antibiotics are commonly prescribed for childhood asthma 354 
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exacerbations,24-26 failure to consider antibiotic prescribing will result in missing a large 355 
number of exacerbations. One study of 60 million asthma exacerbations reported that one in 356 
six pediatric exacerbations were treated with antibiotics. Only 26% of those treated with 357 
antibiotics received corticosteroid treatment (i.e. 12% of all exacerbations)26 and would not 358 
be identified as an exacerbation.       359 
This study has several strengths. We drew on well-maintained and stable datasets 360 
containing medical record information for approximately 15% of children in the UK through 361 
2012. A full baseline year was used for confounder definition. By using a full outcome year, 362 
we could capture infrequent asthma-related events such as exacerbations, and also 363 
eliminate the effect of seasonal variations in allergy. A rigorous matching process was used, 364 
which was informed by our previous work that identified differences between children 365 
receiving LABA as separate inhaler or FDC.10 Matching resulted in two cohorts with similar 366 
demographic characteristics and baseline indicators of asthma severity and control. 367 
Adjustments were made for minor residual confounding. We studied children receiving their 368 
first therapy step-up with add-on LABA, thereby reducing potential effects of declining 369 
persistence with therapy over time.14   370 
Our study has a number of limitations.  First, as in all studies of this nature the patient 371 
outcomes were inferred from prescribing information. This brings the benefits of a large 372 
representative sample size, but it cannot capture aspects of asthma control such as 373 
nocturnal or exertional symptoms, though it can capture use of relieving medication - a valid 374 
index of asthma control.  We cannot rule out the possibility of undetected residual 375 
confounding in this study, although our matching and analytic methods were designed to 376 
minimize this possibility. Despite matching for index date the FDC ICS/LABA cohort was 377 
identified one year after the separate ICS+LABA cohort, reflecting the later introduction of 378 
FDC to clinical practice compared to separate LABA inhaler, but we do not believe that this 379 
difference has substantially affected the outcome.  Our matching ensured that the children in 380 
each cohort were prescribed the same ICS dose (400 µg) but we acknowledge that the 381 
separate ICS+LABA cohort had received less ICS during the baseline year compared to the 382 
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FDC cohort (143 versus 164 µg). Due to the small size of this difference and the fact the 383 
cohorts are well-matched elsewhere, we do not believe that this difference has affected the 384 
difference seen between cohorts. Another potential source of bias is in differential 385 
prescribing with regard to add-on LABA inhaler choice. This could in turn influence 386 
outcomes. Missingness was present but was equally distributed across the two cohorts, e.g. 387 
only 60% of children had height and weight data available. The children with the most severe 388 
asthma, i.e. maintenance oral corticosteroids, were excluded from the analysis and our 389 
results cannot necessarily be extrapolated to this very small group of patients.  We 390 
acknowledge that the definition of asthma used may have resulted in inclusion of children 391 
without asthma and exclusion of children with (unrecognized) asthma, but the aim of this 392 
study was to compare outcomes between groups of children with asthma and not outcomes 393 
between groups with and without asthma. It is unlikely that our inclusion criteria for asthma 394 
diagnosis affected the results.  395 
 In concluding, we used routinely acquired healthcare data to evaluate asthma 396 
treatment benefits in a real world setting. Our results, which are based on data collected 397 
from 2660 children, provide evidence that LABA treatment in children should be 398 
administered as an FDC and not as a separate inhaler.  399 
     400 
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Table I Definitions of database-derived primary and secondary study outcomes.     558 
Study endpoints 
Primary endpoint 
Overall asthma control.  All of the following: no asthma-related hospital admission; no 
emergency room or outpatient attendance for asthma; no prescription for OCS or antibiotic 
with evidence of respiratory consultation; average daily prescribed dose of ≤200 μg/day 
salbutamol or ≤500 μg/day terbutaline (equivalent to ≤2 puffs daily of reliever medication). 
 
Secondary endpoints (determined over 12 months) 
Acute respiratory events 
Acute course of oral corticosteroids (with associated evidence of a respiratory 
consultation) or asthma-related hospitalization or emergency room attendance or 
antibiotic prescription with evidence of a respiratory consultation. 
Rate of severe exacerbations 
Acute course of oral corticosteroids (with associated evidence of a respiratory 
consultation) or asthma-related hospitalization or emergency room attendance 
Risk-domain asthma control:  
No asthma-related hospital admission, emergency room attendance, or unscheduled 
outpatient department attendance, and no prescription for acute course of oral 
corticosteroids with evidence of a respiratory consultation, and no antibiotic 
prescription with evidence of a respiratory consultation. 
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Treatment stability:  
Risk-domain asthma control achieved (see above) and no additional therapy during 
the outcome year.  
 
Definitions of oral corticosteroid use and respiratory consultation are provided in the 559 
supplement. 560 
 561 
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Table II Baseline characteristics of children prescribed add-on LABA as FDC ICS/LABA inhaler or separate ICS+LABA inhalers: 562 
matched cohorts 563 
Characteristic 
FDC ICS/LABA 
(n=1330) 
Separate ICS + 
LABA 
(n=1330) 
p value for difference 
between cohorts 
Male sex, n (%) 780 (58.6) 779 (58.6) 0.97† 
Age at index date, mean (SD) 9.4 (2.2) 9.4 (2.2) n/a† 
Weight categories‡  
Not obese or overweight (i.e. 
<91th BMI centile) 
571 (42.9) 542 (40.8) 
0.11 
Overweight (i.e. 91–97th BMI 
centile) 
118 (8.9) 111 (8.3) 
Obese (i.e. ≥98th BMI centile) 101 (7.6) 136 (10.2) 
Missing BMI data 540 (40.6) 541 (40.7) 
Recorded comorbidity, n Rhinitis diagnosis 295 (22.2) 333 (25.0) 0.083 
  Turner et al.  28 
 
 28 
(%) Eczema diagnosis 664 (49.9) 658 (49.5) 0.81 
Year of index date, median (IQR) 
2006 (2004–
2008) 2005 (2003–2007) <0.001 
Year since first asthma script, median (IQR)  3 (1–5) 3 (1–6) 0.29 
Median (IQR) annualized daily ICS dose, μg/d¶ 143 (82–247) 164 (99–274) 0.001 
ICS dose prescribed before 
index date, n (%) 
≤150 μg/d 0 (0) 0 (0) 
n/a† 
151–250 μg/d 248 (18.6) 248 (18.6) 
251–500 μg/d 1000 (75.2) 1000 (75.2) 
>500 μg/d 82 (6.2) 82 (6.2) 
Median ICS (IQR) ICS dose at index date (μg/d) 400 [400,400] 400 [400, 400] n/a† 
Mean daily SABA dose, 
n (%)¶ 
0 μg/d 21 (1.6) 21 (1.6) 
n/a† 
≤200 μg/d 652 (49.0) 652 (49.0) 
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>200 μg/d 657 (49.4) 657 (49.4) 
†Matching variable. 564 
‡ Cut offs for overweight and obese recommended by the Royal College of Paediatrics and Child Health.41 565 
¶The doses of ICS and SABA were averaged over the baseline year using the formula [number of inhalers x doses per inhaler] divided by 365 566 
x strength (in µg). ICS doses were standardized to equivalence with standard-particle beclomethasone; thus, the actual doses of budesonide 567 
were used, and doses of extrafine beclomethasone and fluticasone were halved. 568 
BMI, body mass index; CPRD, Clinical Practice Research Datalink; FDC, fixed-dose combination; ICS, inhaled corticosteroid; IQR, interquartile 569 
range; LABA, long-acting β-agonist; n/a, not applicable; OPCRD, Optimum Patient Care Database; SD, standard deviation. 570 
  571 
  Turner et al.  30 
 
 30 
Table III Study endpoints, and their components, during the baseline and outcome years. Negative binomial logistic regression models which 572 
yield adjusted. Unadjusted p values are presented here.  Adjusted Odds Ratio and Rate Ratio with p values are presented in Figure I.  573 
Characteristic 
Baseline year Outcome year 
FDC 
ICS/LABA 
(n=1330) 
Separate 
ICS + LABA 
(n=1330) 
p value for 
difference 
between 
groups 
 
FDC 
ICS/LABA 
(n=1330) 
Separate 
ICS + LABA 
(n=1330) 
p value for 
difference 
between 
groups 
during the 
follow up 
years relative 
to baseline 
year without 
adjustment  
Achieve overall asthma control 469 (35.3) 464 (34.7) 0.59 543 (43.1) 495(37.2) 0.001 
Acute respiratory events, mean (SD) 0.49 (0.84) 0.54 (0.92) 0.084 0.32 (0.71) 0.39 (0.75) 0.011 
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Acute respiratory events, 
n (%) 
0 883 (66.4) 857 (64.4) 
0.21 
1031 (77.5) 966 (72.6) 0.003 
1 300 (22.6) 316 (23.8) 217 (16.3) 256 (19.2) 
≥2 147 (11.1) 157 (11.8) 82 (6.2) 108 (8.1) 
Severe exacerbations, n 
(%) 
0 1157 (87.0) 1157 (87.0) 
0.54† 
1237 (93.0) 1205 (90.6) 0.056 
1 136 (10.2) 131 (9.8) 68 (5.1) 98 (7.4) 
≥2 37 (2.8) 42 (3.2) 25 (1.9) 27 (2.0) 
Achieved risk-domain 
asthma control, n (%) 
 846(65.1) 
 
820480 (63.9) 
0.21 
999 (77.4) 973 (72.5) 
0.003 
Achieved treatment stability, 
n (%) 
 
n/a n/a n/a 
842 (65.6)  947 (56.9)     
<0.001 
†Matching variable. Note: severe exacerbations were matched as 0 or ≥1. 574 
FDC, fixed-dose combination; GP, general practice; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β-agonist; n/a, not 575 
applicable; SABA, short-acting β-agonist.576 
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Table IV Asthma therapy prescribed during the outcome year 577 
Outcome 
FDC ICS/LABA 
(n=1330) 
Separate ICS + 
LABA 
(n=1330) 
p value for 
difference 
between 
groups 
SABA inhalers, median (IQR) 3 (2–6) 4 (2–7) <0.001 
Change in therapy (any time), n (%) 244 (18.3) 326 (24.5) <0.001 
Increase in ICS dose ≥50% (any time) 133 (10.0) 58 (4.4) <0.001 
†The doses of ICS and SABA were averaged over the outcome year using the formula 578 
[number of inhalers x doses per inhaler] divided by 365 x strength (in µg). SABA doses were 579 
converted to puffs using the formula 100 µg = 1 puff. The doses of ICS were standardized to 580 
equivalence with standard-particle beclomethasone; thus, the actual doses of budesonide 581 
were used, and doses of extrafine beclomethasone and fluticasone were doubled. 582 
FDC, fixed-dose combination; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, 583 
long-acting β-agonist; n/a, not applicable (comparison not possible because of 0 or low 584 
number); SABA, short-acting β2-agonist. 585 
  586 
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FIGURE LEGEND 587 
 588 
Figure I. Adjusted asthma-related outcome measures comparing matched treatment cohorts 589 
during 1 outcome year. adjOR/adjRR, adjusted odds ratio/rate ratio; FDC, fixed-dose 590 
combination; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; SABA, short-acting 591 
β2-agonist 592 
*p=0.002. Adjusted for nonsteroidal anti-inflammatory drugs 593 
†p=0.012. Adjusted for baseline acute respiratory events and paracetamol prescription 594 
‡p=0.057. Adjusted for baseline severe exacerbations and number of asthma and non-595 
asthma consultations 596 
§p=0.001. Adjusted for paracetamol prescription  597 
¶p=0.001. Adjusted for data source 598 
Figure No.
Click here to download high resolution image
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What is already known about this topic? 38 
Current asthma guidelinesClinical trials provide no evidence to support recommendations 39 
that children with asthma prescribed long-acting β2-agonist (LABA) should receive treatment 40 
as a fixed-dose combination inhaler, rather than and not by  as an additional, of a separate 41 
inhaler to alongside inhaled corticosteroids (ICS). Current literature, however, does not 42 
provide evidence to support this.  43 
What does this article add to our knowledge?  44 
In a matched cohort study, LABA treatment as a separate inhaler was associated with 45 
poorer asthma control and increased risk for exacerbation compared to a fixed-dose 46 
combination inhaler. 47 
How does this study impact current management guidelines? 48 
These findings support recommendations from British Thoracic Society, NICE asthma 49 
guideline and Food and US Drug Administration,  recommendations to prescribe add-on 50 
LABA as a fixed-dose combination inhaler with ICS in children. 51 
  52 
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ABSTRACT  53 
Background Adding a long-acting β2-agonist (LABA) to inhaled corticosteroids (ICS) using a 54 
fixed-dose combination (FDC) inhaler containing ICS and LABA is the UK guideline - 55 
recommendationed step-up option for children aged >4 years with uncontrolled asthma on 56 
ICS monotherapywith uncontrolled asthma. The evidence of benefit of adding a FDC 57 
inhalers over  adding a separate LABA inhaler to ICS therapy is limited.  58 
Objective: Our aim was to compare effectiveness of LABA added as a FDC inhaler, and as 59 
a separate inhaler, in children with uncontrolled asthma. Our aim was to compare outcomes 60 
for FDC versus separate LABA+ICS inhalers for children by analyzing routinely-acquired 61 
clinical and prescribing data. 62 
Methods Two UK primary care databases were used to create aThis matched cohort study 63 
with a two-year follow-up period.  We included used large UK primary care databases to 64 
study children prescribed their first step-up from ICS monotherapy. Two cohorts were 65 
formed, at 5–12 years of age. as add-on LABA, either via separate LABA inhaler or FDC 66 
inhaler. for children receiving add-on LABA as FDC inhaler, or separate LABA inhaler. 67 
Matching variables and confounders were identified by comparing characteristics during aA 68 
baseline year of follow-up.was examined to characterize patients and identify potential 69 
confounders;  Ooutcomes were examined during the subsequent year. The primary outcome 70 
was an adjusted odds ratio for overall asthma control , (defined as; no asthma-related 71 
hospital admission or emergency room visit, prescription for oral corticosteroids or antibiotic 72 
with evidence of respiratory consultation, and ≤2 puffs of short-acting beta-agonist 73 
daily).defined as no asthma-related hospital admission, emergency room visit prescription 74 
for oral corticosteroids and ≤200 μg/day salbutamol. 75 
Results After matching, there wereThe final study consisted of 1330 children in each cohort 76 
(mean age 9 years [SD] 9, [2] years; 59% male). All measures of asthma exacerbations and 77 
control improved during the outcome year in both cohorts. In the separate ICS+LABA cohort, 78 
the odds of achieving overall asthma control were lower (adjusted odds ratio, 0.77 [95% CI, 79 
0.66-0.91] P = 0.001) compared with the FDC cohort.   80 
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Conclusion Our resultsThe study demonstrates a small but significant benefit in achieving 81 
asthma control fromof add-on LABA therapy as FDC, overcompared to a separate inhaler. 82 
which supports current guideline recommendations. 83 
 84 
  85 
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INTRODUCTION 86 
Asthma is common amongst children in the UK, with an estimated 8%, or 1.1 million 87 
children, prescribed current asthma therapy.1,2 The British Thoracic Society and Scottish 88 
Intercollegiate Guidelines Network (BTS/SIGN) guideline for the management of asthma 89 
recommends a stepwise approach to therapy, to maintain symptom control and minimize 90 
future risk of exacerbations. Inhaled corticosteroids (ICS), prescribed at step 2 of the current 91 
BTS/SIGN guideline, are effective controller medications for most children with persistent 92 
asthma.,  For although from  10–25% of children with asthma,  require additional therapy is 93 
required.3-6 For children aged 5-12 years on ICS monotherapy, aAdding a long-acting β2-94 
agonist (LABA) to ICS is the preferred step-up option (step 3) recommended by the 95 
BTS/SIGN when asthma is uncontrolled.for children ages 5–12 years with uncontrolled 96 
asthma on ICS monotherapy.3 97 
 Guidance from the UK National Institute for Health and Care Excellence (NICE) 98 
identifies a fixed-dose combination (FDC) inhaler containing ICS and LABA as the optimal 99 
means of adding a LABA.2, However, preferred over adding LABA as a separate inhaler,2 but 100 
some children continue to be prescribed separate inhalers. One risk of prescribing LABA as 101 
a separate inhaler is its use without concomitant ICS therapy., andThis is a major concern 102 
discussed in the National Review of Asthma Deaths recommended that LABA “should be 103 
prescribed with an inhaled corticosteroid in a single combination inhaler”.7 104 
The benefit of FDC over addition of a separate LABA inhaler to ICS treatment for 105 
children with uncontrolled asthma is unclear. Two clinical trials, where adherence was 106 
closely monitored, found no difference in symptoms after 3 months 8 and 6 months’9 107 
treatment, when comparing between groups randomized to LABA as separate inhaler or 108 
FDC. However, patient behaviours and clinical outcomes are often different in the context of 109 
a clinical trial as opposed to ‘real-life’ usual clinical care. One database study using real-life 110 
data observed a reduced need for short-acting β2-agonist (SABA) and oral corticosteroid 111 
(OCS) treatment in children treated with LABA as an FDC compared with additionalwith a 112 
separate inhaler.4  but importantlyThese results are limited, however, as  there was no 113 
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matching at baseline for factors known to be different between groups, including age and 114 
obesity.10 We have recently reported that children stepped up to LABA as a separate inhaler 115 
are younger and on a lower dose of ICS compared with those stepped up to FDC,.10 and 116 
Tthese baseline differences might explain the apparent superiority of FDC over LABA as 117 
separate inhaler.   118 
Rigorously conducted observational research can provide information about 119 
outcomes of asthma therapy under conditions of usual clinical practice, to complement 120 
information from controlled trials.11 Results of prior retrospective observational studies 121 
suggest that adherence and refill persistence may be better with a combination inhaler, at 122 
least among adults and adolescents.12-14 In turn, better adherence and persistence could 123 
lead to better outcomes. The aim of this large population-based observational study was to 124 
evaluate whethercompare outcomes differ between children with asthma stepped up to add-125 
on LABA as separate vs.inhalers, versus those receiving FDC inhalers. Our hypothesis was 126 
that children stepped up to separate inhalers would have increased reduced odds for poor 127 
achieving asthma control compared with matched children stepped up to FDC. 128 
  129 
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METHODS 130 
Data source and permissions 131 
In a matched cohort study, we sourced medical records and prescribing data from two large 132 
primary care databases including ~15% of children in the UK, as previously described.10 133 
Duplicate records from individual children were identified and removed. The Clinical Practice 134 
Research Datalink (CPRD; formerly General Practice Research Database), which is well-135 
validated and used frequently for observational research, .  It is the world’s largest repository 136 
of anonymized longitudinal data from primary care, drawing from over 600 subscribing 137 
practices throughout the UK.15,16 The Optimum Patient Care Research Database (OPCRD) 138 
is a quality-controlled primary care research database, containing information from over 400 139 
UK practices caring for approximately half a million patients with asthma.]17 thatAs well as  140 
contains anonymous routine medical records, the database contains data and patient-141 
completed questionnaire data. from over 400 practices throughout the UK caring for 142 
approximately a half million patients with asthma.17 Data were available from January 1990 143 
through April 2012 for the Clinical Practice Research DatalinkCPRD  and through December 144 
2012 for the OPCRDOptimum Patient Care Research Database. 145 
 The study was conducted to standards recommended for observational research18 146 
and is registered with the European Network of Centres for Pharmacoepidemiology and 147 
Pharmacovigilance.19 (ref ENCEPP/SDPP/10483). Use of the data was approved in 2010 by 148 
the Independent Scientific Advisory Committee of the (then) General Practice Research 149 
Database. The OPCRD Optimum Patient Care Research Database has been approved by 150 
the Trent Multi Centre Research Ethics Committee for clinical research use, and. Tthe 151 
protocol for this study was approved by the Anonymized Data Ethics Protocols and 152 
Transparency (ADEPT) committee,  - the independent scientific advisory committee for the 153 
Optimum Patient Care Research DatabaseOPCRD. Further background information is 154 
available in the online supplementary material. 155 
Inclusion and exclusion criteria 156 
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Our study included a two-year period of follow-up, consisting of a baseline year and an 157 
outcome year, on either side of an index date. The index date was the point at which step-up 158 
LABA therapy was initiated.  General patient information and events during the baseline year 159 
were used to determine which individuals entered the study sample. Inclusion criteria were: 160 
either a Read read code diagnosis of asthma or with ≥22 or more inhaler prescriptions (at 161 
least 1 of whichincluding ≥1 for was for ICS in the previous 12 months) - (the latter comprise 162 
2% of the study population10); prescribed prescription ofa step-up with LABA, from ICS 163 
monotherapy at 5–12 years of age; registered in the database for ≥2at least 2 sequential 164 
years, including 1 baseline year before the date of therapy step-up (the index date). 165 
Exclusion criteria were: cystic fibrosis or any chronic respiratory disease other than asthma; 166 
receipt of add-on therapy (including combination inhaler) at any time prior to the index date; 167 
treatment with >7 consecutive days oral corticosteroids (OCS) for more than 7 consecutive 168 
days during the baseline year; multiple step-up therapies on the index date; ≥50% increase 169 
or decrease in ICS dose on the index date (the latter ensured that we studied outcomes of 170 
addition of LABA independent of change in ICS).  171 
Study Outcomes 172 
The primary endpoint, previously described19-2120-22, was an adjusted odds ratio (aOR) for 173 
overall asthma control. This compared two study cohorts: those who received step-up LABA 174 
as an FDC inhaler (FDC ICS/LABA cohort), and those who received a separate LABA 175 
inhaler (separate ICS+LABA cohort). (expressed as an adjusted odds ratio, aOR) and 176 
thisThe definition of asthma control includes both components of the American Thoracic 177 
Society/European Respiratory Society2223 definition of asthma control, i.e. the level of clinical 178 
asthma control (as evidenced here by short acting beta agonist use) and the risk of future 179 
adverse events (as evidenced here by a history of adverse events including hospitalisation, 180 
ED emergency visits and receipt of OCS).  Overall The criteria for overall asthma control, as 181 
defined is defined in Ttable 1I, include: no asthma-related hospital admission; no emergency 182 
room or outpatient attendance for asthma; no prescription for OCS or antibiotic with 183 
evidence of respiratory consultation; average daily prescribed dose of ≤200 µg/day 184 
Formatted: Font: Not Italic
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salbutamol or ≤500 µg/day terbutaline (equivalent to ≤2 puffs daily of reliever medication). 185 
Hospital admission, emergency room attendance and unscheduled outpatient attendance 186 
were coded from discharge diagnosis.  A prescription for antibiotics in conjunction with a 187 
respiratory consultation was included in the definition of an acute respiratory event (and 188 
absence of same in the definitions of asthma control) because in clinical practice antibiotics 189 
may be prescribed for an asthma exacerbation.23-,2524-26 Secondary outcomes were acute 190 
respiratory events, severe exacerbations,2623 risk-domain measure of asthma control (to give 191 
insight into risk for future exacerbation)19-2120-22  and treatment stability (see Ttable I1 for 192 
definitions).  Medication use during the 12 months after the index date was also compared 193 
between cohorts.   194 
Calculations of medication use 195 
We calculated the average daily doses of SABA and of ICS during the baseline and outcome 196 
years in the following way: 197 
                                      
   
                          
 as the [number of inhalers x doses per inhaler] divided by 365 multiplied by strength (in µg). 198 
For ICS doses we used the beclomethasone dipropionate (BDP)-equivalent doses for the 199 
calculations, thus: a 1:1 ratio for budesonide: BDP;, a 2:1 ratio for fluticasone propionate: 200 
BDP, and;, and 2:1 1 ratio for extrafine beclomethasone (Qvar): BDP. The ICS medication 201 
possession ratio (MPR) was calculated as: 202 
                                          
   
        
 the number of days coverage of the drug prescribed divided by 365 multiplied by 100 and 203 
expressed as Individuals were <80% categorized as either( non-adherent (MPR<80%), ) 204 
andor adherent ( MPR≥80% (adherent).27,28 The separate LABA inhalers that were available 205 
during the study period contained salmeterol or formoterol; Tthe FDC ICS/LABA inhalers 206 
contained fluticasone-salmeterol (Seretide), budesonide-formoterol (Symbicort), and 207 
extrafine beclomethasone-formoterol (Fostair). 208 
Statistical analyses and sample size 209 
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Children in the two treatment cohorts (separate ICS+LABA and FDC ICS/LABA) were 210 
matched sequentially 1:1 on the following criteria, which were either known to differ at 211 
baselinebase line4: year of index date (±3 years), age (exact year), baseline year number of 212 
severe exacerbations (0 or ≥1) during baseline year, prior ICS daily dose (≤150, 151–250, 213 
251–500, or >500 µg/day), and baseline year mean daily SABA dose (0, 1–200, >200 214 
µg/day) during baseline year. Bespoke software was used to randomly select unique 215 
matched patient pairs when more than one match was possible. 216 
 Data were prepared for analysis by investigating potential outliers, transforming 217 
skewed data (e.g., log transformation), and categorizing heavily skewed data.; Mmissing 218 
data were investigated for type and reason for missingness. All matched unadjusted 219 
baseline and outcome data were tabulated using summary Summary statistics were 220 
computed, by cohort, for baseline characteristics and outcome events. and They were 221 
compared using conditional logistic regression (unadjusted) and an intention-to-treat 222 
analysis, whereby all children were included in the outcome year analyses.. 223 
Conditional logistic regression models were used to estimate adjusted odds ratios 224 
(aOR) and 95% confidence intervals (CIs) for the dichotomous outcomes, such as the 225 
primary endpoint - overall asthma control.  The reference cohort was the FDC ICS/LABA 226 
cohort. 227 
The rates of adverse respiratory events and severe exacerbations during the 228 
outcome year were compared using a negative binomial regression model to. estimate a 229 
Adjusted ratio rate ratios (aRR) were computed and with 95% CIs, with FDC ICS/LABA 230 
cohort as the reference cohort. General estimating equations were used to account for the 231 
correlation within matched pairs.29 The model used empirical standard errors for more robust 232 
confidence intervals (CIs) and adjusted for potential baseline confounders. . 233 
Conditional logistic regression models were used to estimate adjusted odds ratios 234 
(aOR) and 95% CIs for the dichotomous outcomes, e.g. overall asthma control, with FDC 235 
ICS/LABA as the reference, and adjusted for potential confounding factors.  236 
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 For all multivariable models, those variables that were significantly different or 237 
showed a trend towards a difference (P < 0.10) between the treatment cohorts at baseline 238 
were included as potential confounding factors, along with any strongly predictive variables. 239 
Potential confounders examined are listed in the online supplementary material (Table 240 
S1E1). Variables were examined for collinearity and clinical importance and were then 241 
removed in a backwards stepwise procedure until all confounding variables remaining in the 242 
multivariable model had P < 0.1 (see online supplementary material for further details).  243 
All analyses were done on an intention-to-treat basis, i.e. children remained in their 244 
original cohort even if their treatment method changed during the outcome year. Statistical 245 
significance was set at the 5% level, i.e. P < 0.05. 246 
  No prospective power calculation was carried out since our sample size was 247 
determined by the number of eligible children in CPRD the Clinical Practice Research 248 
Datalink and OPCRDOptimum Patient Care Research Database.  249 
The analyses were carried out using IBM SPSS Statistics version 21 (SPSS 250 
Statistics, IBM, Somers, NY, USA), SAS version 9.3 (SAS Institute, Marlow, 251 
Buckinghamshire, UK), and Microsoft Excel 2007 (Microsoft, Bellevue, WA, USA); 252 
statistically significant results were defined as P < 0.05..  253 
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RESULTS 254 
Patients 255 
Overall, 1390 and 3771 children were eligible for the FDC ICS/LABA and separate 256 
ICS+LABA cohorts, respectively (see Ffigure E1 in supplementary file). Ninety seven 257 
percent of children had a diagnosis of asthma and 70% were from OOPCRDthe Optimum 258 
Patient Care Research Database.  After matching there were 1330 children in each cohort, 259 
of mean age (SD) 9 (2) years (SD, 2), and 59% were male (Ttable II2). The two cohorts were 260 
similar in characteristics apart from the separate ICS+LABA cohort having: higher dose of 261 
ICS at baseline, ; higher annualized ICS dose, and; and the LABA step- up occurring one 262 
year earlier (i.e. 2005 versus 2006) compared to the FDC cohort, (Ttable 2 II and Ttable 263 
ES2).The cohorts were well-matched for indicators of baseline asthma severity and control 264 
(Ttable 3III).  265 
 266 
Outcomes 267 
Primary outcome 268 
TIn the FDC ICS/LABA cohort, the proportion of children who achieved overall asthma 269 
control was 35% before the index datea and 43% afterwards. among Equivalent proportions 270 
in the FDC cohort and corresponding proportionsseparate ICS+LABA cohort were 35% and 271 
37% among the ICS+LABA cohort(Table III).; Tthe adjusted odds ratio (aOR) for children in 272 
the separate ICS+LABA cohort achievinge control relative to the FDC ICS/LABA cohort was 273 
0.77 (95% CI, 0.66–0.91; P = 0.001;), table 3, Ffigure I)1.   274 
Secondary outcomes 275 
The rate number of acute respiratory events was greater among the separate ICS+LABA 276 
cohort compared to the FDC ICS/LABA cohort (Table III).group The (adjusted rate ratio 277 
([aRR) was] 1.21;  (95% CI, 1.04–1.39; P = 0.012; table 3, Ffigure I1).  The percentage of 278 
children with ≥1 severe exacerbations was 13% during the baseline year for both cohorts 279 
and in the outcome year was 7% for the FDC ICS/LABA cohort and 9% for the separate 280 
ICS+LABA cohort; . Tthe aRR for severe exacerbations among the children prescribed 281 
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ICS+LABA relative to FDC was 1.31 (95% CI,; 0.99–1.72; P = 0.056; table 3, figure 1). 282 
Relative to the FDC ICS/LABA cohort, children in the separate ICS+LABA as separates 283 
cohort were athad reduced  odds for  achieving risk-domain asthma control (aOR 0.74; 95% 284 
CI, 0.61–0.89; P = 0.003) and achieving treatment stability (aOR 0.67; 95% CI, 0.57–0.79; P 285 
< 0.001), table 3, ; Ffigure I1). There were no significant differences between cohorts for 286 
adherence (MPR>80%) medication possession ratio being >80% or for severe 287 
exacerbations.  In the follow upoutcome year there were 6 hospitalizations for asthma in 288 
each cohort (P = 0.99).  There were 16 children in the FDC ICS/LABA cohort and 3 in the 289 
separates ICS+LABA cohort treated for thrush during the follow up year (P = 0.008, see on 290 
line supplementTable E2).  Compared to the baseline year, more children in the separate 291 
ICS+LABAs cohort (29.9% in baseline year and 19.622.5% in follow up year) received 292 
treatment with antibiotics during the follow- up year than in the FDC cohort (28.6% and 293 
22.519.6% respectively, pP = 0.041).  There was a trend which approached significance for 294 
a greater proportion of the separates separate ICS+LABA cohort to receive oral 295 
corticosteroidOCSs compared to the FDC ICS/LABA cohort during the outcome follow up 296 
year (8.8% versus 6.5%, p=0.084). but no difference in the number with asthma-related 297 
hospital admissions and GP consultations for asthma.  298 
Asthma prescribing during outcome year 299 
Asthma therapy prescribed during the outcome year, as well as changes in therapy, are 300 
summarized in Ttable 4IV. Children in the FDC ICS/LABA cohort typically received one 301 
fewer SABA inhalers in the outcome year (3 versus 4, table 4) compared with those in the 302 
separate ICS+LABA cohort (3 vs. 4 inhalers; P < 0.001)as separates. Children in the FDC 303 
ICS/LABA cohort were more likely to have an increase in ICS dose compared with those in 304 
the separate ICS+LABA cohortas separates  (10% vs. 4%; P < 0.001), but no more likely to 305 
have LTRA added. Seventeen percent of children in the ICS+LABA as separates cohort 306 
were started on an FDC during the outcome year. The proportion of children achieving 307 
adherencewith ( MPR>80%) was 33% in the FDC ICS/LABA cohort and was 31% for in the 308 
separate ICS+LABA as separates cohort (aOR 0.87; 95% CI,  [0.72–1.06]). During the 309 
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outcome year the median daily ICS dose was 219 μg for both cohorts., Further, during the 310 
outcome year 231 (18%) children in the separate ICS+LABAs cohort  switched to FDC, and 311 
17 (1%) children  in the FDC ICS/LABA cohort  switched to a separate LABA inhaler.s and 312 
LTRA treatment was started in 122 in the FDC ICS/LABA cohort (9%) and 112 in the 313 
separates ICS+LABA cohort (8%).  314 
 315 
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DISCUSSION 316 
The aim of this matched cohort study was to provide evidence to support guidelines 317 
recommending recommendations that children receiving LABA as an add-on to ICS 318 
treatment should be prescribed a fixed-dose combination inhaler (FDC) and not an 319 
additional, separate LABA inhaler., It is an important point to establish as prescribing 320 
prescription of separate inhalerss remains very common in UK clinical practice, despite 321 
recommendations .2,3 The main finding was that children prescribed add-on LABA with ICS 322 
as separate inhalers had a 3023% reduced odds of having controlled asthma compared with 323 
children prescribed FDC.  Additionally the use of separate inhalers was associated with a 324 
21% greater exacerbation rate of acute respiratory events compared with those who 325 
received FDC. The fact that 17% of children in the separate ICS+LABA cohort were 326 
prescribed an FDC inhaler during the outcome year suggests that prescribers may be trialing 327 
LABA as a separate inhaler., but oOur data suggest that the trial should be with FDC in the 328 
first instance. Our results provide additional evidence that supports guideline 329 
recommendations for LABA to be prescribed as FDC, and not as a separate, inhaler.2,3    330 
Although significant, the improvement in outcomes for those treated with FDC was 331 
only improved by a small degree compared with treatment with separate ICS and LABA 332 
inhalers. (figure 1).  We used an intention-to-treat analysis, but know thatas 17% of the 333 
separate ICS+LABA cohort received FDC during the follow up, and  this will underestimate 334 
the true clinical benefit of FDC over separate ICS+LABA inhalers.   We present our results 335 
as odds ratios, and the effect size is small when presented as a likelihood ratio for achieving 336 
control (0.9 for the separates ICS+LABA cohort compared to the FDC ICS/LABA cohort), or 337 
as the number needed to treat (17 children would require treatment with FDC instead of a 338 
separate inhaler in order to meanfor  one additional child to achieved asthma control).  This 339 
small effect may be partly explained by improvement in all outcomes in both groups as the 340 
children became older.  An additional factor may be that adherence was relatively poor for all 341 
participants (22-33%) and poor adherence is associated with poor control.30 This may have 342 
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led to the decision to step-up and also to a relatively disappointing response to treatment.  343 
National guidelines3 recommend that before initiating a new drug therapy, adherence to 344 
existing therapies should be considered, as well as inhaler technique and the elimination of 345 
trigger factors. The adherence in our study suggests that this may not be happening 346 
routinely.An additional factor may be that adherence was relatively poor for all participants 347 
(22-33%).  Overall, relatively few children prescribed LABA in our study achieved overall 348 
asthma control (35-43%), and whilst this is partly related to the moderate severity of their 349 
disease this study highlights the burden of respiratory morbidity in children with asthma 350 
which can be at least partly improved by FDC prescription in place of ICS and LABA 351 
separates, typically one fewer SABA canister per annum. 352 
 There is little prior published work comparing outcomes with FDC versus separate 353 
inhalers for children prescribed add-on LABA, yet many thousands of children are prescribed 354 
LABA each year. Outcomes were similar with FDC versus separate inhalers for children in 355 
two relatively short double-blind, double-dummy trials with relatively short duration,8,9 356 
although one trial did observe a greater increase in peak expiratory flow in children receiving 357 
FDC compared with ICS+LABA asto separate inhalerss.9 These studies8,9 might have been 358 
underpowered to detect differences between two effective treatments, and additionally it is 359 
well-recognized that clinical trials recruit individuals whose disease is exceptionally stable 360 
and whose adherence behavior is not generalizable to the whole population. and Tthis 361 
potentially reduces the ability of clinical trials to detect  a difference in outcome between 362 
treatment groups.18 A recent retrospective observational database study observed that 363 
children prescribed FDC inhalers received fewer acute oral corticosteroid courses and, in 2 364 
of the 4 years studied, also less reliever medication than those prescribed separate 365 
inhalers.4  One possible explanation for the findings of Elkout et al.4 is that the apparent 366 
benefit of FDC is due to children receiving separates being at increased risk for adverse 367 
outcomes per se and our previous work confirms that younger children are more likely to be 368 
prescribed separate inhalers10 and are also more likely to have exacerbations.30 The present 369 
study applied a matched cohort analysis and although there were small differences between 370 
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cohorts in ICS dose at baseline where any effect would minimize any benefit of step up to 371 
FDC we are able to conclude that the benefit of FDC over separates is not explained by 372 
differences at baseline.    373 
 374 
 The use of an FDC ICS/LABA inhaler has several theoretical benefits over two 375 
separate inhalers. The concurrent delivery of a bronchodilator (LABA) may provide a 376 
symptomatic benefit with use of FDC inhalers that promotes inhaler use, and thus may lead 377 
to improved adherence with treatment and increased consumption of concomitant ICS.31,32 378 
Other authors have hypothesized there may be a biochemical synergy between ICS and 379 
LABA with their co-deposition in the airways.33,34 Moreover, an important advantage of 380 
combining ICS and LABA in one inhaler is the prevention of LABA use as monotherapy, 381 
which carries potential increased risk of asthma-related mortality. and Ssince 2005 LABA 382 
monotherapy is accompanied by a Food and Drug Administration (FDA) “black box” warning 383 
in the US.35,36 A In 2010, the FDA recommended the use of FDC products to ensure 384 
compliance with concomitant therapy in pediatric and adolescent patients.ation was that “a 385 
FDC product…be used to ensure compliance with concomitant therapy in pediatric and 386 
adolescent patients”.37 Conversely, an advantage of prescribing separate inhalers is the 387 
ability to titrate ICS dose independently of the LABA. 388 
 The assumption of better LABA adherence with use of a single FDC ICS/LABA 389 
inhaler rather than two separate inhalers is generally acknowledged.2 We found no evidence 390 
for improved ICS adherence between cohorts, in terms of refill prescription rates., but 391 
However, the increased number of children treated for thrush in the FDC ICS/LABA 392 
compared to the separate ICS+LABA cohorts might suggest increased adherence with ICS 393 
in the FDC cohort,  but may reflect a lower proportion using a spacer device compared to the 394 
separates cohort.  Some retrospective observational studies find that FDC inhalers are 395 
associated with better adherence and refill persistence by both adults and adolescents with 396 
asthma,12-14 but this finding is not seen in all studies. For example, in one randomized 397 
controlled trial (patients ages aged 16–65 years) where covert  electronic monitoring was 398 
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used to measure adherence,,  similar adherence was found with FDC and separate inhaler 399 
therapy.38 In a retrospective observational study, and consistent with our findings, Elkout et 400 
al.39 found that MPR was similar for children prescribed separate ICS and +LABA inhalers 401 
and FDC LABA/ICSonly. Further, and it is possible that although separate ICS and LABA 402 
inhalers are issued with equal frequency, adherence with ICS is higher compared with 403 
separate LABA separateinhalers. Clearly more research is needed in this area but the 404 
limited data from children presented here and from adults elsewhere38 suggest that FDC is 405 
associated with superior outcomes compared with ICS plus LABA as separates and . 406 
Potentially, this difference may be explained by different taking behavior, e.g. taking more 407 
separates inhalers when symptomatic. 408 
 Treatment with a “SMART” regimen40 (which utilizes a combination inhaler with both 409 
preventer and reliever medication) has never been recommended for children in the UK, and 410 
our study cannot give insight into the potential benefits of this practice.  There is evidence of 411 
reduced exacerbations in children randomized to a “SMART” regimen compared with 412 
FDC4041 but this work has not been confirmed elsewhere or incorporated into guidelines to 413 
date.  414 
Antibiotics are not recommended for the treatment of acute asthma excerbations in 415 
any age group, but since antibiotics are commonly prescribed for childhood asthma 416 
exacerbations,23-2524-26  failure to consider antibiotic prescribing will result in missing a large 417 
number of exacerbations.  One study of 60 million asthma exacerbations reported that one in 418 
six pediatric exacerbations were treated with antibiotics., and  Oonly 26% of those treated 419 
with antibiotics received corticosteroid treatment (i.e. 12% of all exacerbations)2526 and would 420 
not be identified as an exacerbation.       421 
This study has several strengths. We drew on well-maintained and stable datasets 422 
containing medical record information for approximately 15% of children in the UK through 423 
2012. A full baseline year was used for confounder definition., Byand  using a full outcome 424 
year for examining asthma-related outcomes to , we could capture infrequent asthma-related 425 
events such as exacerbations, and also eliminate the effect of seasonal variations in allergy. 426 
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A rigorous matching process was used, which was informed by our previous work that 427 
identified differences between children receiving LABA as separate inhaler or FDC.,10 and 428 
thisMatching resulted in two cohorts with similar demographic characteristics and baseline 429 
indicators of asthma severity and control.; Aadjustments were made for minor residual 430 
confounding. We studied children receiving their first therapy step-up with add-on LABA, 431 
thereby reducing potential effects of declining persistence with therapy over time.14   432 
Our study has a number of limitations.  First, as in all studies of this nature the patient 433 
outcomes were inferred from prescribing information. whichThis brings the benefits of a large 434 
representative sample size,  but which but it cannot capture aspects of asthma control such 435 
as nocturnal or exertional symptoms, however we are able tothough it can capture use of 436 
relieving medication which is- a valid index of asthma control.  We cannot rule out the 437 
possibility of undetected residual confounding in this study, although our matching and 438 
analytic methods were designed to minimize this possibility. Despite matching for index data 439 
date the FDC ICS/LABA cohort was identified one year after the separate ICS+/LABA 440 
cohort, reflecting the later introduction of FDC to clinical practice compared to separate 441 
LABA inhaler, but we do not believe that this difference has substantially affected the 442 
outcome.  Our matching ensured that the children in each cohort were prescribed the same 443 
ICS dose (400 µg) but we acknowledge that the separates separate ICS+LABA cohort had 444 
received less ICS duringover the previous baseline year compared to the FDC cohort (143 445 
versus 164 µg). Due to the small size of this difference and the fact the cohorts are well-446 
matched elsewhere, and  we do not believe that this difference has affected the difference 447 
seen between cohorts.  Moreover, as in any observational study there was the potential for 448 
bias, for example,Another potential source of bias is in differential prescribing with regard to 449 
add-on LABA inhaler choice. This that could in turn influence outcomes. Missingness was 450 
present but was equally distributed across the two cohorts, e.g. only 60% of children had 451 
height and weight data available. The children with the most severe asthma, i.e. 452 
maintenance oral corticosteroids, were excluded from the analysis and our results cannot 453 
necessarily be extrapolated to this very small group of patients.  Children with small changes 454 
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in ICS dose than recommended (i.e. <50%) were also excluded from our analysis meaning 455 
that our results cannot be extrapolated to this clinical setting.  We acknowledge that the 456 
definition of asthma used may have resulted in inclusion of children without asthma and 457 
exclusion of children with (unrecognized) asthma, but the aim of this study was to compare 458 
outcomes between groups of children with asthma and not outcomes between groups with 459 
and without asthma. so It is unlikely that ourthe inclusion criteria for asthma diagnosis are 460 
not likely to affected the results.  461 
 In concluding, we used routinely acquired healthcare data are a valuable source for 462 
determiningto evaluate asthma treatment benefits in a real world setting and complement 463 
results from clinical trials.. Our results, which are based on data collected from 2660 464 
children, provide evidence that for the whole population LABA treatment in children should 465 
be administered as an FDC and not as a separate inhaler.  466 
     467 
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 629 
Table I1 Definitions of database-derived primary andstudy secondary study outcomes.    630 
Definitions of oral corticosteroid use and respiratory consultation are provided in the 631 
supplement. 632 
Study endpoints 
Primary endpoint 
Overall asthma control.  All of the following: no asthma-related hospital admission; no 
emergency room or outpatient attendance for asthma; no prescription for OCS or antibiotic 
with evidence of respiratory consultation; average daily prescribed dose of ≤200 μg/day 
salbutamol or ≤500 μg/day terbutaline (equivalent to ≤2 puffs daily of reliever medication). 
 
Secondary endpoints (determined over 12 months) 
Acute respiratory events 
Acute course of oral corticosteroids (with associated evidence of a respiratory 
consultation) or asthma-related hospitalization or emergency room attendance or 
antibiotic prescription with evidence of a respiratory consultation. 
Rate of severe exacerbations* 
Acute course of oral corticosteroids (with associated evidence of a respiratory 
consultation) or asthma-related hospitalization or emergency room attendance 
Risk-domain asthma control:  
No asthma-related hospital admission, emergency room attendance, or unscheduled 
outpatient department attendance, and no prescription for acute course of oral 
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corticosteroids with evidence of a respiratory consultation, and no antibiotic 
prescription with evidence of a respiratory consultation. 
Treatment stability:  
Risk-domain asthma control achieved (see above) and no additional therapy during 
the outcome year.  
 
Definitions of oral corticosteroid use and respiratory consultation are provided in the 633 
supplement. 634 
 635 
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Table II2 Baseline characteristics of children prescribed add-on LABA as FDC ICS/LABA inhaler or separate ICS+LABA inhalers: 636 
matched cohorts 637 
Characteristic 
FDC ICS/LABA 
(n=1330) 
Separate ICS + 
LABA 
(n=1330) 
p value for difference 
between cohorts 
Male sex, n (%) 780 (58.6) 779 (58.6) 0.97† 
Age at index date, mean (SD) 9.4 (2.2) 9.4 (2.2) n/a† 
Weight categories‡  
Not obese or overweight (i.e. 
<91th BMI centile) 
571 (42.9) 542 (40.8) 
0.11 
Overweight (i.e. 91–97th BMI 
centile) 
118 (8.9) 111 (8.3) 
Obese (i.e. ≥98th BMI centile) 101 (7.6) 136 (10.2) 
Missing BMI data 540 (40.6) 541 (40.7) 
Recorded comorbidity, n Rhinitis diagnosis 295 (22.2) 333 (25.0) 0.083 
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(%) Eczema diagnosis 664 (49.9) 658 (49.5) 0.81 
Year of index date, median (IQR) 
2006 (2004–
2008) 2005 (2003–2007) <0.001 
Year since first asthma script, median (IQR)  3 (1–5) 3 (1–6) 0.29 
Median (IQR) annualized daily ICS dose, μg/d¶ 143 (82–247) 164 (99–274) 0.001 
ICS dose prescribed before 
index date, n (%) 
≤150 μg/d 0 (0) 0 (0) 
n/a† 
151–250 μg/d 248 (18.6) 248 (18.6) 
251–500 μg/d 1000 (75.2) 1000 (75.2) 
>500 μg/d 82 (6.2) 82 (6.2) 
Median ICS (IQR) ICS dose at index date (μg/d) 400 [400,400] 400 [400, 400] n/a† 
Mean daily SABA dose, 
n (%)¶ 
0 μg/d 21 (1.6) 21 (1.6) 
n/a† 
≤200 μg/d 652 (49.0) 652 (49.0) 
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>200 μg/d 657 (49.4) 657 (49.4) 
†Matching variable. 638 
‡ Cut offs for overweight and obese recommended by the Royal College of Paediatrics and Child Health.41 639 
¶The doses of ICS and SABA were averaged over the baseline year using the formula [number of inhalers x doses per inhaler] divided by 365 640 
x strength (in µg). ICS doses were standardized to equivalence with standard-particle beclomethasone; thus, the actual doses of budesonide 641 
were used, and doses of extrafine beclomethasone and fluticasone were doubledhalved. 642 
BMI, body mass index; CPRD, Clinical Practice Research Datalink; FDC, fixed-dose combination; ICS, inhaled corticosteroid; IQR, interquartile 643 
range; LABA, long-acting β-agonist; n/a, not applicable; OPCRD, Optimum Patient Care Database; SD, standard deviation. 644 
  645 
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Table III3 Study endpoints, and their components, during the baseline and outcome years. Negative binomial logistic regression models which 646 
yield adjusted. Unadjusted p values are presented here.  Adjusted Odds Ratio and Rate Ratio with p values are presented in figure Figure oneI.  647 
Characteristic 
Baseline year Outcome year 
FDC 
ICS/LABA 
(n=1330) 
Separate 
ICS + LABA 
(n=1330) 
p value for 
difference 
between 
groups 
 
FDC 
ICS/LABA 
(n=1330) 
Separate 
ICS + LABA 
(n=1330) 
p value for 
difference 
between 
groups 
during the 
follow up 
years relative 
to baseline 
year without 
adjustment  
Achieve overall asthma control 469 (35.3) 464 (34.7) 0.59 543 (43.1) 495(37.2) 0.001 
Acute respiratory events, mean (SD) 0.49 (0.84) 0.54 (0.92) 0.084 0.32 (0.71) 0.39 (0.75) 0.011 
  Turner et al.  35 
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Acute respiratory events, 
n (%) 
0 883 (66.4) 857 (64.4) 
0.21 
1031 (77.5) 966 (72.6) 0.003 
1 300 (22.6) 316 (23.8) 217 (16.3) 256 (19.2) 
≥2 147 (11.1) 157 (11.8) 82 (6.2) 108 (8.1) 
Severe exacerbations, n 
(%) 
0 1157 (87.0) 1157 (87.0) 
0.54† 
1237 (93.0) 1205 (90.6) 0.056 
1 136 (10.2) 131 (9.8) 68 (5.1) 98 (7.4) 
≥2 37 (2.8) 42 (3.2) 25 (1.9) 27 (2.0) 
Achieved risk-domain 
asthma control, n (%) 
 846(65.1) 
 
820480 (63.9) 
0.21 
999 (77.4) 973 (72.5) 
0.003 
Achieved treatment stability, 
n (%) 
 
n/a n/a n/a 
842 (65.6)  947 (56.9)     
<0.001 
†Matching variable. Note: severe exacerbations were matched as 0 or ≥1. 648 
FDC, fixed-dose combination; GP, general practice; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β-agonist; n/a, not 649 
applicable; SABA, short-acting β-agonist.650 
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Table IV4 Asthma therapy prescribed during the outcome year 651 
Outcome 
FDC ICS/LABA 
(n=1330) 
Separate ICS + 
LABA 
(n=1330) 
p value for 
difference 
between 
groups 
SABA inhalers, median (IQR) 3 (2–6) 4 (2–7) <0.001 
Change in therapy (any time), n (%) 244 (18.3) 326 (24.5) <0.001 
Increase in ICS dose ≥50% (any time) 133 (10.0) 58 (4.4) <0.001 
†The doses of ICS and SABA were averaged over the outcome year using the formula 652 
[number of inhalers x doses per inhaler] divided by 365 x strength (in µg). SABA doses were 653 
converted to puffs using the formula 100 µg = 1 puff. The doses of ICS were standardized to 654 
equivalence with standard-particle beclomethasone; thus, the actual doses of budesonide 655 
were used, and doses of extrafine beclomethasone and fluticasone were doubled. 656 
FDC, fixed-dose combination; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, 657 
long-acting β-agonist; LTRA, leukotriene receptor antagonist; n/a, not applicable 658 
(comparison not possible because of 0 or low number); SABA, short-acting β2-agonist. 659 
  660 
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FIGURE LEGEND 661 
 662 
Figure I1. Adjusted asthma-related outcome measures comparing matched treatment 663 
cohorts during 1 outcome year. adjOR/adjRR, adjusted odds ratio/rate ratio; FDC, fixed-dose 664 
combination; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; SABA, short-acting 665 
β2-agonist 666 
*p=0.002. Adjusted for nonsteroidal anti-inflammatory drugs 667 
†p=0.012. Adjusted for baseline acute respiratory events and paracetamol prescription 668 
‡p=0.057. Adjusted for baseline severe exacerbations and number of asthma and non-669 
asthma consultations 670 
§p=0.001. Adjusted for paracetamol prescription  671 
¶p=0.001. Adjusted for data source 672 
 673 
 674 
 675 
 FDC vs. LABA step-up: children_Online supplement_V1.0_2July2015 1 
Online data repository 
 
Long-acting beta-agonist in combination or separate inhaler as step-up therapy for children with uncontrolled asthma 
receiving inhaled corticosteroids 
 
S. Turner et al 
 
  
Repository - Unmarked E Tables
 FDC vs. LABA step-up: children_Online supplement_V1.0_2July2015 2 
Table E1. Potential confounding factors considered in this study: 
Potential confounders examined at (or closest to) the relevant index date: 
 Age  
 Sex 
 Smoking status 
 Body Mass Index (BMI) centile categorised including a ‘missing’ category where BMI was not 
available. All BMI centile values for individuals beyond ±5 standard deviations were excluded 
as likely outliers.* 
 Weight category (obese, overweight or non-obese/non-overweight*† 
Potential confounders examined regardless of when they occurred relative to the index date: 
 Date of first asthma diagnosis (where known); 
 Other respiratory or other confounding diagnoses, including: rhinitis, gastro-oesophageal 
reflux disease (GERD), eczema, and cardiac disease.   
Potential confounders examined in the year before the index date: 
 Number of primary care consultations, both asthma- and non-asthma-related; 
 Number of hospital outpatient attendances where asthma is recorded as the reason for 
referral ; 
 Number of in-patients admissions for asthma; 
 Number of ER attendances for asthma; 
 Number of ER attendances or in-patient admissions for lower respiratory reasons; 
 Number of prescriptions for antibiotics with evidence of respiratory review; 
 Acute oral steroid use associated with asthma exacerbation treatment; 
 Prescriptions for other medications that might interfere with asthma control: beta-blockers, 
NSAIDs and paracetamol; 
 Number of prescriptions for asthma and/or allergies; 
 SABA daily dosage;  
 Average ICS daily dose;  
 ICS dose at index date. 
In addition: 
 Year of index date 
 Previous step-up recorded in the database  
 Time between first asthma prescription and the index date (0-1 years, > 1 year) 
 Database (OPCRD vs. CPRD) 
 FDC vs. LABA step-up: children_Online supplement_V1.0_2July2015 3 
* Both BMI centiles and IOTF Grade were calculated using Imsgrowth macro software; Microsoft Excel add-in, version 1.12. 
† Non-overweight/non-obese was defined as BMI index <91
st
. Overweight was defined as BMI centile ≥91
st
 and <98
th
.  Obese was defined as BMI 
centile ≥98th. 
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Table E2. Additional study outcomes during the baseline and outcome years 
 Baseline year Outcome year 
Characteristic 
FDC ICS/LABA 
(n=1330) 
Separate  
ICS + LABA 
(n=1330) 
p 
Value* 
FDC ICS/LABA 
(n=1330) 
Separate  
ICS + LABA 
(n=1330) 
p value* 
≥1 asthma-related ED attendance, n (%)  6 (0.5) 6 (0.5) 1.0 2 (0.2) 6 (0.5) 0.18 
≥1 asthma-related OPD visit, n (%) 15 (1.1) 11 (0.8) 0.44 5 (0.4) 7 (0.5) 0.57 
Total GP consultations, median (IQR) 6 (3–9) 6 (3–9) 0.77 5 (3–8) 5 (2–8) 0.38 
GP consultation not for asthma, median 
(IQR) 
3 (2–6) 4 (2–6) 
0.86 3 (1–6) 3 (1–5) 
0.19 
Spacer device prescribed, n (%) 366 (27.5) 379 (28.5) 0.57 257 (19.3) 334 (25.1) <0.001 
Thrush, n (%)† 10 (0.8) 9 (0.7) 0.81 16 (1.2) 3 (0.2) 0.008 
*Matched cohorts were compared using conditional logistic regression. 
†Thrush was defined as a Read code for oral candidiasis or topical antifungal prescription definitely for treating oral candidiasis. 
ED, Emergency Department; FDC, fixed-dose combination; GP, general practice; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β-
agonist; OPD, outpatient department. 
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SUPPLEMENTARY METHODS 
The study was conducted to standards suggested for observational studies, including an 
independent advisory group (all authors), use of an a priori analysis plan, study registration 
with commitment to publish, and well-maintained and monitored study databases.[1] Funding 
for the analyses was provided by the Respiratory Effectiveness Group (REG),[2] and the 
study was registered with the European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance (ENCePP).[3] The analyses and the dissemination of the results were 
conducted in accordance with the REG standards and the ENCePP Code of Conduct.[4]  
 
Definitions of outcomes 
For the severe exacerbation and acute respiratory event definitions, any criteria occurring 
within 2 weeks of each other were counted as one exacerbation/event. 
An acute course of oral corticosteroids was defined as (i) prescribing instructions that 
suggested an exacerbation (reducing dose over time or 30 mg prednisolone as directed), (ii) 
a course without prescribing instructions but unlikely to be maintenance therapy and with a 
code for asthma or lower respiratory event, (iii) not maintenance therapy (defined as 
prescribed daily dose of <10 mg prednisolone or prescription for 1 mg prednisolone tablets. 
Evidence of a respiratory consultation was defined as any lower respiratory Read codes 
(asthma, chronic obstructive pulmonary disease, or lower respiratory infection codes) or 
codes for any additional respiratory examinations, referrals, chest radiographs, or events. 
emergency room; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LTRA, 
leukotriene receptor antagonist.   
 
Statistical analyses 
Variables that differed between treatment groups with p<0.10 were examined for collinearity 
and clinical importance to select those used as potential confounders in the regression 
modelling of outcomes. In addition, multivariable analyses were used to identify baseline 
variables that were predictive (at p<0.05) of each outcome variable during the outcome 
period; these were considered as potential confounders when modelling the outcome 
variables. Spearman correlation coefficients were calculated between all potential 
confounders to determine strengths of linear relationships between variables. The correlation 
coefficients were considered, in conjunction with clinical interpretation, to identify pairings of 
variables that might present collinearity issues at the modelling stage. In general, collinearity 
was considered an issue for relationships with rank correlation coefficients >0.30. Potential 
confounders examined are listed in Table E1. 
 
Figure Legend 
Figure E1 Patient selection and matching: Patients in the two treatment cohorts were 
matched on clinically and demographically important characteristics. 
CPRD, Clinical Practice Research Datalink; FDC, fixed-dose combination ICS/LABA; ICS, 
inhaled corticosteroid; index date, date of first prescription for FDC ICS/LABA or separate 
ICS+LABA; LABA, long-acting β2-agonist; OCS, oral corticosteroid; OPCRD, Optimum 
Patient Care Research Database; SABA, short-acting β2-agonist. 
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